Celcuity Inc. (CELC) Stock Price & How to Invest
Last updated November 2026
Short answer
Celcuity (CELC) is a newly commercial oncology company whose value rides almost entirely on gedatolisib, its breast-cancer drug, which the FDA approved on July 14, 2026 as REVTORPYK and which began shipping in the US on September 30, 2026. A position is now effectively a bet on the launch and on a second, larger label for PIK3CA-mutant patients, which the FDA accepted for review in November 2026 with a June 25, 2027 goal date, rather than on current earnings. The stock has been volatile: at about $54 on November 20, 2026 it is down roughly 46% for the year and trading near its 52-week low.
CELC stock price
As of 2026-11-20, Celcuity Inc. (CELC) last closed at $53.35, down 45.3% over the past year. Over the past 52 weeks it has traded between $53.35 and $144.98.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Celcuity Inc.'s investor relations page. Walnut is informational, not investment advice.
CELC key stats
At $53.35 on November 20, 2026, Celcuity Inc. (CELC) has a market cap of $2.6B.
- Market cap
- $2.6B
- Beta
- 0.13
Market cap, P/E and yield are measured at the $53.35 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Celcuity Inc. (CELC)?
The last two weeks for Celcuity Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- CELC closed at $53.35 on November 20, 2026, down 17.1% over the past five trading days (from $64.37).
- On November 9, 2026, HC Wainwright & Co. lowered its target to $150.00 from $155.00 (Buy).
Celcuity Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Celcuity Inc. (CELC) do?
Celcuity Inc. is a Minneapolis-based biotechnology company focused on targeted therapies for solid tumors. Its lead product, gedatolisib, is a pan-PI3K/AKT/mTOR (PAM) inhibitor for HR+/HER2- advanced breast cancer. Unlike single-node inhibitors such as alpelisib, capivasertib, and everolimus, gedatolisib is designed to block the whole pathway at once. The registrational Phase 3 VIKTORIA-1 trial hit its primary endpoint, with gedatolisib combination regimens roughly doubling progression-free survival versus alpelisib plus fulvestrant in the PIK3CA-mutant cohort, results presented at ASCO. On July 14, 2026, three days ahead of its PDUFA goal date, the FDA approved gedatolisib as REVTORPYK for adults with HR+/HER2-, PIK3CA wild-type, locally advanced or metastatic breast cancer that progressed after at least one line of endocrine therapy in the metastatic setting, used with fulvestrant with or without palbociclib. Celcuity submitted a supplemental NDA for the PIK3CA-mutant population in August 2026, announced US commercial availability on September 30, 2026, and on November 9, 2026 said the FDA had accepted the sNDA with a PDUFA goal date of June 25, 2027.
The investment picture has moved from the classic pre-approval setup to an early launch: a large addressable market and strong trial data on one side, and still negligible product revenue, rising spending and concentrated single-asset risk on the other. The third quarter of 2026 recorded no product revenue, because no product reached providers or pharmacies until after September 30, and the net loss was about $73.3 million, with an adjusted loss of $1.21 per share against a -$1.53 estimate. Early launch indicators reported in November were that 78% of the top 36 strategic accounts had ordered the drug, 91% of US commercial and Medicare lives were in plans covering it, and it carried an NCCN preferred Category 1 recommendation for second-line and later therapy. In June the company sold about $575 million of 0.25% convertible notes due 2032 (conversion price about $124.53) and used about $137 million to prepay term debt; after a $50 million approval milestone paid to Pfizer, it ended September with roughly $643 million of cash and short-term investments, which management expects to fund operations through 2029. The stock has not followed the approval higher: at about $54.42 on November 20, 2026 it is down about 46% year to date, about 41% over three months and about 42% over one year. Consensus expects about $13.6 million of revenue in the fourth quarter of 2026 and roughly $284 million in 2027. The launch trajectory, the sNDA outcome and the VIKTORIA-2 first-line program are the variables that matter most. Walnut is not an investment adviser, and a name like this carries outcomes that can swing sharply on single regulatory or clinical events.
What's driving Celcuity Inc. (CELC)?
1. REVTORPYK launch execution
The FDA approval on July 14, 2026 converted Celcuity from a pre-revenue developer into a commercial-stage company, and the drug began shipping in the US on September 30, 2026. Early prescription trends, payer coverage, manufacturing and the build-out of a first salesforce are now the main tests. By early November, 78% of the top 36 strategic accounts (about half the addressable patients) had ordered, more than 3,400 sites had engaged with sales specialists, and 91% of US commercial and Medicare lives were covered. Consensus looks for about $13.6 million of revenue in the fourth quarter, the first with sales, and about $32 million in the first quarter of 2027, so the early launch quarters will be read against a low bar but a steep 2027 ramp.
2. The PIK3CA-mutant label
The approved label covers PIK3CA wild-type patients. The wider PIK3CA-mutant opportunity, where VIKTORIA-1 showed the combinations improved median progression-free survival by roughly 5.5 to 5.7 months versus alpelisib plus fulvestrant, is the subject of a supplemental NDA that the FDA accepted in November 2026 with a PDUFA goal date of June 25, 2027. At ESMO 2026 the company presented mutant-cohort data for patients without liver metastases: median progression-free survival of 21.5 months for the triplet and 11.5 months for the doublet versus 9.1 months for alpelisib plus fulvestrant, with fewer discontinuations for side effects. If approved, the drug would be available as second-line therapy regardless of PIK3CA status.
3. Differentiated pan-pathway mechanism
Gedatolisib blocks all four class I PI3K isoforms plus mTORC1 and mTORC2, aiming to close the adaptive-resistance loops that single-target drugs can leave open. If the trial profile holds in real-world use, it supports a premium position within the PAM-inhibitor class.
4. Label-expansion pipeline
Beyond the initial indications, the Phase 3 VIKTORIA-2 program is studying gedatolisib in first-line advanced breast cancer, including endocrine-sensitive and endocrine-resistant patients, and an early study pairs it with darolutamide in metastatic castration-resistant prostate cancer, where Phase 1b/2 data were shown at ESMO 2026 and a randomized Phase 2 is planned for the first half of 2027. Additional cohorts and combination regimens broaden the potential eligible population over time, and each readout is a discrete catalyst that can move the shares independent of the base indication.
What are the risks to Celcuity Inc. (CELC)?
Celcuity is still essentially a single-product company, so a slow launch, a delay or narrow outcome on the PIK3CA-mutant sNDA (goal date June 25, 2027), or disappointing later cohort data could sharply reduce the value the market assigns. The stock fell about 17% in the month to November 20, 2026 and is down about 46% for the year despite approval and an accepted second filing, which shows how harshly it is being judged on early commercial signals. It lost about $256 million over the trailing twelve months, spending is rising with the launch, and stockholders' equity turned negative at September 30, 2026. The June 2026 convertible offering removed near-term funding pressure (about $643 million of cash at September 30, a runway management puts through 2029), but it also added about $575 million of convertible debt that can dilute holders if converted at about $124.53 a share, and total debt on the balance sheet is about $755 million. Commercial uptake faces entrenched and newly approved competitors, payer and pricing pressure, and the operational challenge of a first launch. The stock has been volatile and can gap on single events, which is characteristic of small biotech rather than a defect specific to this name.
What is the Celcuity Inc. (CELC) forecast?
13 analysts publish price targets on CELC, averaging $150.85 as of November 2026, or +182.8% against the $53.35 share price on November 20, 2026. The published targets run from $130.00 to $177.00, a moderate spread, and the ratings split 13 buy, 0 hold, 0 sell. Over the last six months there has been 1 raise and 6 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full CELC forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is CELC a buy or a sell?
We give no verdict on Celcuity Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. REVTORPYK launch execution. The FDA approval on July 14, 2026 converted Celcuity from a pre-revenue developer into a commercial-stage company, and the drug began shipping in the US on September 30, 2026. The most optimistic published target, $177.00, assumes this works close to its best case.
The case against. Celcuity is still essentially a single-product company, so a slow launch, a delay or narrow outcome on the PIK3CA-mutant sNDA (goal date June 25, 2027), or disappointing later cohort data could sharply reduce the value the market assigns. The most pessimistic target, $130.00, is roughly what CELC is worth if this bites instead.
Read the full bull and bear case on CELC, including what would have to change to break either one. Walnut is not an investment adviser.
Has Celcuity Inc. (CELC) split its stock?
No. Celcuity Inc. (CELC) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is Celcuity Inc. (CELC) valued?
Market cap, P/E and dividend yield at today's price are in the CELC key stats above. The business figures below come from Celcuity Inc.'s reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$0 (first shipments September 30, 2026); Q4 2026 consensus ~$13.6M
- Q3 2026 net loss / adjusted EPS: ~$73.3M / -$1.21 vs -$1.53 estimate
- Net loss (TTM): ~$256M
- Cash & short-term investments: ~$643M (September 30, 2026)
- Debt: ~$755M, including ~$575M of 0.25% convertibles due 2032, conversion ~$124.53
- 2027 revenue consensus: ~$284M
As of November 2026: Because Celcuity has only just begun selling REVTORPYK, standard multiples like price-to-earnings or price-to-sales still do not apply, and the market cap of about $2.7 billion reflects the expected value of the launch and label expansion. Debt of about $755 million now exceeds cash of about $643 million, and management expects the cash to fund operations through 2029. Analysts' mean target near $151 across 13 analysts sits far above the November 20, 2026 price of $54.42, a gap that reflects how differently forecasts and the market are reading the launch.
Who competes with Celcuity Inc. (CELC)?
Approved PI3K/AKT/mTOR pathway drugs
Alpelisib (Novartis, a PI3K-alpha inhibitor), capivasertib (AstraZeneca, an AKT inhibitor), and everolimus (mTORC1 inhibitor) are already approved with endocrine therapy in HR+/HER2- advanced breast cancer. They are the direct comparators gedatolisib was measured against and the incumbents REVTORPYK now has to displace in the clinic.
Emerging pathway and resistance-targeting agents
Newer entrants such as inavolisib and other PI3K/AKT-pathway candidates target the same resistance biology in overlapping patient populations. Competition here shapes how much of the market gedatolisib can win and at what price, particularly in the PIK3CA-mutant population covered by the pending sNDA.
Broader HR+/HER2- treatment options
CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) and endocrine therapies frame the standard of care that gedatolisib combinations slot into or follow. Sequencing decisions and combination partners determine where gedatolisib fits in the treatment pathway; the approved label pairs it with fulvestrant, with or without palbociclib.
What stocks are similar to Celcuity Inc. (CELC)?
Other names that sit close to CELC: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Celcuity Inc. (CELC)
There are three common ways to get CELC exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CELC sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where CELC fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Celcuity Inc. (CELC)
CELC is a single-product biotech that cleared its biggest regulatory hurdle in July 2026 and is now judged on launch uptake, the PIK3CA-mutant supplemental filing due for an FDA decision by June 25, 2027, and how far roughly $643 million of cash stretches, which keeps it high-reward and high-risk in equal measure.
More on Celcuity Inc. (CELC)
Whether CELC is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CELC a buy or a sell?, and where the stock could go from here in the CELC stock forecast.
For income investors, whether CELC pays a dividend and how the payout looks is covered in does CELC pay a dividend? And to weigh CELC against a peer, read the full side-by-side comparisons: CELC vs NVS and CELC vs AZN.
Wondering how CELC fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Celcuity Inc.
Ask Walnut's AI anything about CELC and see how it fits what you own.
FAQ
What does Celcuity do?
+
Celcuity is a biotechnology company developing and now selling targeted cancer therapies. Its lead drug, gedatolisib, is a pan-PI3K/AKT/mTOR inhibitor approved in July 2026 as REVTORPYK for a subset of HR+/HER2- advanced breast cancer, and the company also runs diagnostic and functional-testing work supporting its programs.
Does Celcuity make any money yet?
+
Not yet. REVTORPYK began shipping in the US on September 30, 2026, but no product reached providers or pharmacies until after that date, so reported revenue through September 2026 was zero, and the third quarter net loss was about $73.3 million. Consensus expects about $13.6 million of revenue for the fourth quarter of 2026 and about $284 million for 2027.
What is gedatolisib?
+
Gedatolisib, sold as REVTORPYK, is Celcuity's lead drug, an intravenously administered inhibitor that blocks all four class I PI3K isoforms plus mTORC1 and mTORC2. The design aims to suppress the whole pathway at once and reduce the adaptive resistance that single-target drugs can trigger.
What is the FDA PDUFA date for gedatolisib?
+
The PDUFA goal date for the PIK3CA wild-type indication was July 17, 2026, and the FDA approved the drug early, on July 14, 2026, as REVTORPYK. The label covers adults with HR+/HER2-, PIK3CA wild-type advanced breast cancer that progressed after at least one line of endocrine therapy in the metastatic setting, used with fulvestrant with or without palbociclib. A supplemental NDA for PIK3CA-mutant disease was submitted in August 2026, and on November 9, 2026 Celcuity said the FDA had accepted it with a PDUFA goal date of June 25, 2027.
What did the VIKTORIA-1 trial show?
+
The registrational Phase 3 VIKTORIA-1 trial met its primary endpoint. In the PIK3CA-mutant cohort, gedatolisib combination regimens roughly doubled the likelihood of survival without disease progression versus alpelisib plus fulvestrant, improving median progression-free survival by about 5.5 to 5.7 months. Updated results presented at ESMO in October 2026 for mutant-cohort patients without liver metastases showed median progression-free survival of 21.5 months on the triplet and 11.5 months on the doublet, versus 9.1 months on alpelisib plus fulvestrant, and response rates of 59% and 43% versus 33%.
Who competes with gedatolisib?
+
Approved pathway drugs including alpelisib, capivasertib, and everolimus are the direct comparators, alongside emerging agents such as inavolisib. In the broader HR+/HER2- setting, gedatolisib combinations sit within a standard of care shaped by CDK4/6 inhibitors and endocrine therapies.
Why is CELC considered a high-risk stock?
+
Its value rests largely on one drug, so launch, regulatory or clinical setbacks can move the shares sharply. The stock fell about 46% in 2026 through November 20 even after FDA approval, a sign of how much depends on early sales and the second label, and it carries about $755 million of debt, mostly convertible notes, against about $643 million of cash.
How much cash does Celcuity have?
+
Celcuity reported about $643 million in cash, cash equivalents, and short-term investments at September 30, 2026, down from about $754 million at June 30 after quarterly operating cash use of about $66 million and a $50 million approval milestone paid to Pfizer. Earlier in 2026 it raised about $575 million through 0.25% convertible notes due 2032 and prepaid about $137 million of term debt. Management expects the cash to fund operations through 2029.
How has CELC stock performed in 2026?
+
As of November 20, 2026 CELC closed at $54.42, down about 46% year to date, about 41% over three months, about 17% over the past month and about 42% over one year. The 52-week range is roughly $53.54 to $151.02, so the stock sits near its low.
How did Celcuity do in its latest quarter?
+
In the third quarter of 2026, reported November 5, Celcuity had no product revenue and a net loss of about $73.3 million, with an adjusted loss of $1.21 per share against a -$1.53 estimate, up from an adjusted $0.78 loss a year earlier as launch spending rose. Cash ended the quarter at about $643 million. Four days later the FDA accepted the PIK3CA-mutant sNDA with a June 25, 2027 goal date. The fourth quarter will be the first with REVTORPYK sales, with consensus near $13.6 million.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Celcuity Inc.'s investor relations page or your broker before making investment decisions.